Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Rhea-AI Summary

Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, reporting provider momentum to move gene-, cell- and tissue-based treatments into outpatient and community settings to improve access and patient experience.

The report surveyed >160 clinicians and administrators, notes 61 approved advanced therapies in the U.S. today and projects that total will nearly triple by 2030, while highlighting infrastructure, staffing and partnership needs for safe community delivery.

Positive

• 61 approved advanced therapies in the U.S. today
• Pipeline expected to nearly triple by 2030
• Survey of >160 clinicians shows broad support for community expansion (majority agreement)

Negative

• Nearly 48% of community respondents said program readiness took 1–2 years
• Significant infrastructure and staffing investments required for community delivery

News Market Reaction – CAH

+0.36%

+0.36% Session close to close

In the Apr 14 session, CAH gained 0.36%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Cardinal Health’s role in enabling advanced therapies beyond inpatient ...

Analysis

This announcement highlights Cardinal Health’s role in enabling advanced therapies beyond inpatient hospitals, citing perspectives from more than 160 providers and 61 currently approved therapies in the U.S. It reinforces themes seen in prior reports on biosimilars and specialty areas, emphasizing partnerships between health systems and community practices. Investors may track how these insights translate into concrete programs, required infrastructure investments, and future disclosures around specialty services growth and capital deployment.

Key Figures

Survey participants: more than 160 physicians and administrators Approved advanced therapies: 61 therapies Partnership importance (strongly agree): 54% +5 more

8 metrics

Survey participants more than 160 physicians and administrators Advanced Therapies Report respondent base

Approved advanced therapies 61 therapies Currently approved in the U.S.

Partnership importance (strongly agree) 54% Health system respondents on community–system partnerships

Partnership importance (agree) 43% Health system respondents on community–system partnerships

Community shift boosts capacity (agree) 63% Health system respondents on moving therapies into community

Community shift boosts capacity (strongly agree) 33% Health system respondents on moving therapies into community

Program preparation time 48% need 1–2 years Community respondents on preparing to administer advanced therapies

Current share price $214.18 Trading level before this news, 8.31% below 52-week high

Historical Context

5 past events · Latest: Apr 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Capacity expansion	Positive	+0.3%	Expanded Actinium-225 production to support more targeted cancer therapies.
Mar 24	Earnings date set	Neutral	+0.4%	Announced date and webcast details for Q3 FY26 earnings release.
Mar 23	Board leadership change	Neutral	-0.7%	Appointed Patricia A. Hemingway Hall as Board Chair upon predecessor’s retirement.
Feb 24	Biosimilars report	Positive	+0.5%	Released biosimilars report highlighting large cost savings and strong provider confidence.
Feb 12	Dividend declaration	Positive	+2.7%	Board approved quarterly dividend of $0.5107 per share payable April 15, 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company news and thought-leadership reports have typically coincided with mild positive price reactions, while governance changes drew a small negative move.

Recent Company History

Over the past few months, Cardinal Health has highlighted growth and strategic positioning through multiple updates. The February 10-Q showed strong revenue and earnings growth, followed by a February 24 biosimilars report emphasizing large cost savings and high provider confidence. Subsequent news covered dividends, leadership changes, and an April 1 expansion of Actinium-225 production capacity. Today’s advanced therapies report fits this pattern of showcasing Cardinal Health’s role in evolving care models and specialty therapeutics.

Key Terms

advanced therapies, gene-, cell-, tissue-based treatments, +4 more

8 terms

advanced therapies medical

"Research confirms advanced therapies are moving beyond inpatient hospitals, with providers"

Advanced therapies are medical treatments that use living cells, genes, or engineered tissues to repair, replace or reprogram parts of the body rather than treating symptoms with traditional drugs. Think of them as swapping out or reprogramming faulty parts of a machine instead of using oil to keep it running — they can offer long‑lasting or one‑time solutions for serious diseases. For investors, these therapies can mean high development costs, big regulatory hurdles, and the potential for large returns if they become approved and widely adopted.

gene- medical

"Advanced therapies are innovative gene-, cell- and tissue-based treatments that target"

Gene- is a prefix meaning related to genes or genetic material — the instructions inside living cells that determine traits and guide biological processes. For investors, seeing this prefix in product names, trial descriptions, or business lines signals work involving genetic-based science or therapies, which can mean higher research costs, longer regulatory paths, and potentially large rewards if successful; think of it like backing a company building a new kind of engine rather than improving an existing car.

cell- medical

"Advanced therapies are innovative gene-, cell- and tissue-based treatments that target"

cell- is a prefix indicating that a product, therapy, test, or process involves living biological cells—the basic units of life such as immune cells or engineered tissue. For investors it flags technologies and regulatory paths that differ from conventional drugs, often meaning more complex manufacturing, specialized facilities and higher development costs, but also the potential for outsized returns if the approach proves effective; think of it as custom-made versus mass-produced solutions.

tissue-based treatments medical

"gene-, cell- and tissue-based treatments that target the root cause of disease"

Tissue-based treatments use cells or pieces of human or animal tissue as the active part of a medical therapy to repair, replace, or regenerate damaged body parts—think of them as biological “patches” or repair kits applied to injured or diseased tissue. For investors, these therapies matter because their value depends on clinical effectiveness, manufacturing consistency, regulatory approval, and reimbursement; successful products can address large unmet needs but often carry higher development, production, and regulatory risk than conventional drugs.

oncology medical

"Oncology remains the dominant therapeutic area, though innovation is accelerating across"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

neurology medical

"innovation is accelerating across additional disease states such as neurology, rheumatology,"

Neurology is the branch of medicine that studies the brain, spinal cord and nerves and the disorders that affect them, from headaches and seizures to movement and memory problems. Investors track neurology because research breakthroughs, clinical trial results and new treatments can change a healthcare product’s market potential, regulatory approval path and revenue outlook—like a key software update that can make a gadget suddenly much more valuable.

rheumatology medical

"innovation is accelerating across additional disease states such as neurology, rheumatology,"

A medical specialty that diagnoses and treats disorders of the joints, muscles, bones and immune system, such as arthritis, lupus and other inflammatory conditions. Investors care because advances in rheumatology—new drugs, diagnostic tests or treatment guidelines—can change demand, pricing and long-term healthcare costs for companies in pharmaceuticals, biotech and medical devices, much like a breakthrough part changes performance and value for an entire car model line.

ophthalmology medical

"disease states such as neurology, rheumatology, ophthalmology and cardiology, among others."

Ophthalmology is the branch of medicine that diagnoses, treats and prevents eye diseases and vision problems, ranging from routine exams to surgery. For investors, it matters because advances, approvals or setbacks in eye drugs, surgical tools, diagnostics or implants can change sales, regulatory risk and long-term demand—think of it as the medical ‘repair and upgrade’ market for a vital organ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes.

DUBLIN, Ohio, April 14, 2026 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, offering new insights into how the expanding advanced therapy pipeline is reshaping sites of care. Advanced therapies are innovative gene-, cell- and tissue-based treatments that target the root cause of disease by repairing, replacing or regenerating damaged cells, offering long-term benefits for many conditions. As more therapies shift to outpatient and community-based settings, the report underscores strong provider momentum to improve access, flexibility and the overall patient experience.

The report draws on perspectives from more than 160 physicians and administrators across community practices and health systems, alongside expert commentary and a patient case study illustrating the real-world impact of outpatient advanced therapy administration.

Key findings include:

• Strong provider support for expanding advanced therapy administration into outpatient and community-based settings.
• Broad agreement that partnerships between health systems and community practices are critical to ensuring safe, high-quality care.
• Significant operational, clinical and economic planning is required to establish advanced therapy programs, particularly in community settings.
• Growing opportunity to improve patient access and experience by delivering life-changing therapies closer to home.

"Advanced therapies are transforming care for patients with complex and serious diseases, often delivering outcomes that were not possible just a decade ago," said Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health. "As these therapies evolve, access must also expand. Our report encouragingly underscores the growing momentum to move treatment closer to patients' homes — while emphasizing the partnerships, infrastructure and planning required to do so safely and sustainably."

There are currently 61 advanced therapies approved in the U.S., with that number expected to nearly triple by 2030, according to Cardinal Health's pipeline analysis. Oncology remains the dominant therapeutic area, though innovation is accelerating across additional disease states such as neurology, rheumatology, ophthalmology and cardiology, among others. Today, most oncology advanced therapies are still administered in inpatient academic or health system settings, but providers across the ecosystem are actively working to expand care to community-based sites of care to increase patient access.

Our survey findings show broad alignment around the benefits of shifting advanced therapies into community settings and demonstrate the need for collaboration to make the shift possible.

• Nearly all health system respondents strongly agreed (54%) or agreed (43%) that partnerships between community practices and health systems are essential to ensure optimal outcomes.
• Nearly all health system respondents agreed (63%) or strongly agreed (33%) that moving advanced therapies into the community would increase health system capacity for emerging innovative treatments.

Establishing advanced therapy programs requires deliberate planning, infrastructure investment and cross‑organizational coordination. Nearly half of community respondents (48%) reported that preparing to administer advanced therapies took one to two years, reflecting the operational and clinical complexity involved. Health systems pointed to investments in technology to support care coordination, while community practices emphasized expanding specialized staff and building new workflows. Community providers also highlighted that partnership models offering after-hours triage support, clinical training and expedited referral pathways are critical enablers of safe, scalable advanced therapy delivery.

To read the full 2026 Advanced Therapies Industry Report, visit cardinalhealth.com/cellandgene.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Learn more at cardinalhealth.com and in our Newsroom.

Contacts
Media: Casey Sudzina, Casey.Sudzina@cardinalhealth.com and (614) 536-3220 and
Investors: Matt Sims, Matt.Sims@cardinalhealth.com and (614) 553-3661 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-report-highlights-growing-momentum-to-expand-advanced-therapies-into-community-care-settings-302740909.html

SOURCE Cardinal Health

FAQ

What did Cardinal Health report say about moving advanced therapies into community care (CAH) on April 14, 2026?

The report said community expansion is gaining momentum with provider support and partnership needs. According to the company, survey data from >160 clinicians emphasize partnerships, planning and investment are essential to shift advanced therapies safely into outpatient settings.

How many advanced therapies does Cardinal Health say are approved in the U.S. (CAH) and what is the outlook to 2030?

Cardinal Health reported 61 advanced therapies approved today and forecasts near-tripling by 2030. According to the company, oncology leads today while neurology, rheumatology, ophthalmology and cardiology are accelerating innovation across the pipeline.

What operational timelines did Cardinal Health find for community practices preparing to administer advanced therapies (CAH)?

About 48% of community respondents said preparing programs took one to two years. According to the company, this reflects planning, staffing and workflow development needed to manage clinical and logistical complexity in community settings.

What partnerships and investments does Cardinal Health recommend for safe community advanced therapy delivery (CAH)?

Cardinal Health emphasizes partnerships between health systems and community practices plus investments in staffing and technology. According to the company, after-hours triage, clinical training, care-coordination tech and expedited referral pathways are critical enablers.

How does Cardinal Health's report say community expansion of advanced therapies affects health system capacity (CAH)?

The report indicates moving therapies to the community can increase health system capacity for innovative treatments. According to the company, 63% agreed and 33% strongly agreed that community delivery would expand system capacity for emerging therapies.